MARKET

NRIX

NRIX

Nurix Therapeutics, Inc.
NASDAQ
11.27
+0.11
+0.99%
After Hours: 11.27 0 0.00% 16:20 05/02 EDT
OPEN
11.35
PREV CLOSE
11.16
HIGH
11.56
LOW
11.18
VOLUME
595.17K
TURNOVER
0
52 WEEK HIGH
29.56
52 WEEK LOW
8.18
MARKET CAP
859.18M
P/E (TTM)
-4.0125
1D
5D
1M
3M
1Y
5Y
1D
Breaking Down Nurix Therapeutics: 7 Analysts Share Their Views
Benzinga · 3d ago
Nurix Therapeutics Price Target Maintained With a $27.00/Share by Needham
Dow Jones · 3d ago
Innovative Capabilities and Promising Data Drive Buy Rating for Nurix Therapeutics
TipRanks · 3d ago
Needham Reiterates Buy on Nurix Therapeutics, Maintains $27 Price Target
Benzinga · 3d ago
Nurix Therapeutics Presents Data at AACR 2025 Highlighting Transformative Potential of Proprietary DEL-AI Platform Leveraging Machine Learning To Speed Discovery Of Novel Drugs
Benzinga · 4d ago
Weekly Report: what happened at NRIX last week (0421-0425)?
Weekly Report · 4d ago
Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets
Barchart · 04/25 12:00
Cathie Wood Buys More NVIDIA And AMD Stock As Chinese Tech Giants Stockpile Chips Amid Looming US Export Curbs
Benzinga · 04/24 01:23
More
About NRIX
More
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.
Recently
Symbol
Price
%Change

Webull offers Nurix Therapeutics Inc stock information, including NASDAQ: NRIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRIX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NRIX stock methods without spending real money on the virtual paper trading platform.